@veiledleaks For everyone around the world who once believed in American democracy as a model to follow, his presidency has been nothing short of catastrophic.
In this planned interim analysis of a randomized trial, first surveillance colonoscopy at 5 years after the removal of high-risk adenomas was noninferior to first colonoscopy at 3 years for the incidence of colorectal cancer. Full EPoS II trial results: https://t.co/ABnbAOKBZh
Editorial: When More Is Not Better — Colonoscopy Surveillance after High-Risk Adenomas https://t.co/B2jICCLBuv
Correspondence: Colorectal Cancer Risk among Patients with Serrated Polyps (EPoS III trial) https://t.co/hENNrFoHVI
@bcherny Fable 5 keeps flagging normal medical content (drug dosing, IBD therapy) in my clinical app — your own error admits it flags safe content. Unusable for medicine. 4 reports ignored. Req: req_011Ccvu97KhAEeYAXutwFys2
Fair point on early disease — but in established, biologic-exposed patients the 'it matters less which therapy' logic breaks down fast. Comorbidities, safety constraints, prior exposures all narrow the field significantly. That's exactly the complexity I've been trying to systematize. #GITwitter #IBD
@APandT Network meta-analyses give you efficacy rankings — but real sequencing decisions also depend on prior exposure, comorbidities, and safety constraints. Built a prototype that tries to integrate all these variables explicitly. #IBD#GITwitter
@LancetGastroHep Biomarker-guided selection is one piece — the other is what happens after infliximab fails. Sequencing logic across guidelines is still poorly systematized. Been working on a decision-support prototype for exactly this. #ECCO2026#GITwitter
Dmitry Peskov's statement is unacceptable but in line with the systematic effort of the Russian Federation to manipulate and interfere with democratic processes in Romania. The Kremlin finds that it is failing, hence the frustration.